Literature DB >> 19002790

Mechanisms of resistance to alkylating agents.

G Damia1, M D'Incalci.   

Abstract

Alkylating agents are the most widely used anticancer drugs whose main target is the DNA, although how exactly the DNA lesions cause cell death is still not clear. The emergence of resistance to this class of drugs as well as to other antitumor agents is one of the major causes of failure of cancer treatment. This paper reviews some of the best characterized mechanisms of resistance to alkylating agents. Pre- and post-target mechanisms are recognized, the former able to limit the formation of lethal DNA adducts, and the latter enabling the cell to repair or tolerate the damage. The role in the pre-target mechanisms of reduced drug accumulation and the increased detoxification or activation systems (such as DT-diaphorase, metallothionein, GST/GSH system, etc...) are discussed. In the post-target mechanisms the different DNA repair pathways, tolerance to alkylation damage and the 'downstream' effects (cell cycle arrest and/or apoptosis) are examined.

Entities:  

Year:  1998        PMID: 19002790      PMCID: PMC3449574          DOI: 10.1023/A:1008060720608

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  86 in total

1.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage.

Authors:  P Branch; G Aquilina; M Bignami; P Karran
Journal:  Nature       Date:  1993-04-15       Impact factor: 49.962

2.  Reconstitution of human DNA repair excision nuclease in a highly defined system.

Authors:  D Mu; C H Park; T Matsunaga; D S Hsu; J T Reardon; A Sancar
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

3.  Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.

Authors:  L Sreerama; N E Sladek
Journal:  Biochem Pharmacol       Date:  1993-06-22       Impact factor: 5.858

4.  DNA minor groove binding ligands: a new class of anticancer agents.

Authors:  M D'Incalci; C Sessa
Journal:  Expert Opin Investig Drugs       Date:  1997-07       Impact factor: 6.206

5.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

6.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.

Authors:  J C Huang; D B Zamble; J T Reardon; S J Lippard; A Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

7.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

Authors:  M Belanich; M Pastor; T Randall; D Guerra; J Kibitel; L Alas; B Li; M Citron; P Wasserman; A White; H Eyre; K Jaeckle; S Schulman; D Rector; M Prados; S Coons; W Shapiro; D Yarosh
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

8.  Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.

Authors:  H A Dirven; B van Ommen; P J van Bladeren
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione.

Authors:  M G Bolton; J Hilton; K D Robertson; R T Streeper; O M Colvin; D A Noe
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

View more
  8 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

2.  A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy.

Authors:  Maria K Lagou; Dimitra P Anastasiadou; George S Karagiannis
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

3.  Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Authors:  Nathalie Gaspar; Swee Y Sharp; Simon Pacey; Chris Jones; Michael Walton; Gilles Vassal; Suzanne Eccles; Andrew Pearson; Paul Workman
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

4.  Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer.

Authors:  Moumita Maji; Subhendu Karmakar; Arnab Gupta; Arindam Mukherjee
Journal:  Dalton Trans       Date:  2020-02-25       Impact factor: 4.390

5.  Cleavage of Abasic Sites in DNA by an Aminoquinoxaline Compound: Augmented Cytotoxicity and DNA Damage in Combination with an Anticancer Drug Chlorambucil in Human Colorectal Carcinoma Cells.

Authors:  Chandra Sova Mandi; Tridib Mahata; Dipendu Patra; Jeet Chakraborty; Achyut Bora; Ritesh Pal; Sanjay Dutta
Journal:  ACS Omega       Date:  2022-02-18

Review 6.  Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.

Authors:  Mohamed Haider; Amr Elsherbeny; Valeria Pittalà; Valeria Consoli; Maha Ali Alghamdi; Zahid Hussain; Ghalia Khoder; Khaled Greish
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

Review 7.  Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation.

Authors:  Agnieszka Potęga
Journal:  Molecules       Date:  2022-08-17       Impact factor: 4.927

8.  Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence.

Authors:  Pramod Kumar Sharma; Arup Kumar Misra; Vikram Singh; Ajay Gupta; Shrishti Saroha; Surjit Singh
Journal:  J Pharmacol Pharmacother       Date:  2016 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.